Affordable Access

deepdyve-link
Publisher Website

Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease

Authors
  • Pfeil, Julia1
  • Hoenig, Merle C.1, 2
  • Doering, Elena1, 3
  • van Eimeren, Thilo1, 3, 4
  • Drzezga, Alexander1, 2, 3
  • Bischof, Gérard N.1
  • 1 Department of Nuclear Medicine, Multimodal Neuroimaging Group, University of Cologne, University Hospital of Cologne, Cologne, Germany
  • 2 Research Center Juelich, Institute for Neuroscience and Medicine II, Molecular Organization of the Brain, Juelich, Germany
  • 3 German Center for Neurodegenerative Diseases, Bonn/Cologne, Germany
  • 4 University of Cologne, University Hospital of Cologne, Department of Neurology, Cologne, Germany
Type
Published Article
Journal
Neurobiology of Aging
Publisher
Elsevier
Publication Date
Oct 01, 2021
Volume
106
Pages
119–129
Identifiers
DOI: 10.1016/j.neurobiolaging.2021.06.014
PMID: 34284259
PMCID: PMC8461082
Source
PubMed Central
Keywords
Disciplines
  • Article
License
Unknown

Abstract

Although beta-amyloid (Aβ) positivity has shown to be associated with higher risk of progression to Alzheimer's disease (AD) in mild cognitive impairment (MCI), information on the time to conversion to manifest dementia cannot be readily deduced from this binary classification. Here, we assessed if regional patterns of Aβ deposition measured with 18F-florbetapir may serve as biomarker for progression risk in Aβ-positive cognitively normal (CN) and MCI patients, including clinical follow-up data and cerebrospinal fluid (CSF) biomarkers. Voxel-wise group comparisons between age and sex-matched Aβ-positive groups (i.e., CN-stables [n = 38] vs. CN-to-MCI/AD progressors [n = 38], MCI-stables [n = 104] versus MCI-to-AD progressors [n = 104]) revealed higher Aβ burden in precuneus, subcortical, and parietal regions in CN-to-MCI/AD progressors and cingulate, temporal, and frontal regions in MCI-to-AD progressors. Importantly, these regional patterns predicted progression to advanced stages on the AD spectrum in the short and the long-term beyond global Aβ burden and CSF biomarkers. These results suggest that distinct regional patterns of Aβ burden are a valuable biomarker for risk of disease progression in CN and MCI.

Report this publication

Statistics

Seen <100 times